- Interim data from Cohort 1 of Phase 2 REDWOOD-HCM study evaluating Cytokinetics' (NASDAQ:CYTK) CK-274 for hypertrophic cardiomyopathy, showed that patients experienced substantial reductions in the average resting left ventricular outflow tract gradient, a predictor of heart failure and cardiovascular death.
- These decrease in pressure gradients were achieved with only modest decreases in average left ventricular ejection fraction (LVEF), refers to the amount of blood being pumped out of the left ventricle (heart's main pumping chamber).
- There were no dose interruptions due to LVEF falling below 50%, the prespecified safety threshold.
- In addition, the safety and tolerability data were supportive of continued dose escalation with no serious adverse events reported.
- Based on the results, the Steering Committee and Data Monitoring Committee have recommended that the trial proceed to Cohort 2. Enrollment is expected to complete in Q1 2021 and full results from REDWOOD-HCM across both Cohort 1 and Cohort 2 are expected in mid-2021.
- CK-274 is a small molecule cardiac myosin inhibitor.
- In September, the company initiated Phase 1 study with its second myosin inhibitor in hypertrophic cardiomyopathy.